Tahoe Therapeutics closes 30 million round to power virtual cell models

A Palo Alto biotech firm closes a 30 million round to scale data generation for virtual cell modeling and AI driven drug discovery.

Tahoe Therapeutics Raises 30 Million to Build Virtual Cell Models

Tahoe Therapeutics announced a 30 million funding round led by Amplify Partners, boosting its total funding to 42 million and valuing the company at 120 million. The capital will accelerate Tahoe’s push to expand Tahoe-100M, a dataset of 100 million single cell perturbations showing how cancer cells react to more than 1 000 molecules. The company uses its Mosaic platform to assemble cells from many patients and organs, building large data atlases that feed its AI models.

Arc Institute recently used Tahoe-100M as part of its open source State model training, with the benchmark showing stronger accuracy than earlier efforts. Tahoe aims to grow its data to more than a billion datapoints to power virtual cell models and speed up the search for new cancer medicines. Management also indicates it may partner with a major pharma or AI company to share data and expand its reach while keeping the bulk of its larger datasets proprietary.

This funding signals a shift toward data scale as the main asset in AI driven biology. By prioritizing mass data generation, Tahoe is betting that bigger single cell datasets will yield more reliable models and faster drug discovery. The company blends patients’ cells to create diverse, scalable datasets, a move that could redefine what is considered core IP in biotech.

At the same time, the model depends on long term collaboration and careful navigation of data ownership, regulatory review, and commercial partnerships. The real test will be translating virtual cell models into safe, effective medicines and proving that data scale translates into tangible patient benefits rather than hype.

Highlights

The path from data to medicine remains a long one, but Tahoe has built a clear data moat.